Drug Profile

Tenecteplase - Genentech

Alternative Names: IA TNK; Metalyse; Recombinant tissue plasminogen activator-Genentech; RG-3625; TNK; TNK-tPA; TNKase

Latest Information Update: 16 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Boehringer Ingelheim; Genentech; Roche Canada
Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
Mechanism of Action Plasminogen activators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Myocardial infarction; Stroke
Phase II SARS-CoV-2 acute respiratory disease
Discontinued Catheter thrombosis; Heart arrest

Most Recent Events

03 Mar 2025 Launched for Stroke in USA (IV)
03 Mar 2025 Registered for Stroke in USA (IV)
26 Dec 2023 3841904 - No updates (phase-IV trial data - NCT02777580)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com